BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS) (NCT06773910)
An Open-label, Randomized Study of BMS-986489 (Atigotatug + Nivolumab Fixed-dose Combination) vs Durvalumab as Consolidation Therapy Following Chemoradiotherapy in Limited-stage Small-cell Lung Cancer (TIGOS-LS)
🩺 Plain-English Summary (8th-Grade Level)
This is an open-label, randomized study of BMS-986489 (atigotatug + nivolumab fixed-dose combination) vs durvalumab in limited-stage (LS)-small-cell lung cancer (SCLC) participants. The main goals of this study are to: * Evaluate the efficacy of BMS-986489 vs durvalumab * Evaluate the safety profile of BMS-986489
Who can join: Review the eligibility criteria below.
Location: Southern Cancer Center — Daphne, Alabama
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (34 Sites)
Showing the first 25 of 34 sites.
- Southern Cancer Center — Daphne, Alabama
- Sansum Clinic — Santa Barbara, California
- Florida Cancer Specialists - South — Fort Myers, Florida
- University of Miami - Sylvester Cancer Center — Miami, Florida
- Ocala Oncology Center — Ocala, Florida
- Florida Cancer Specialists - North — Orange City, Florida
- Cancer Care Centers of Brevard — Palm Bay, Florida
- Florida Cancer Specialists - East — West Palm Beach, Florida
- Piedmont Healthcare - Atlanta — Atlanta, Georgia
- Illinois Cancer Specialists — Arlington Heights, Illinois
- Illinois Cancer Care — Peoria, Illinois
- Indiana University Simon Cancer Center — Indianapolis, Indiana
- Baptist Health - Corbin — Corbin, Kentucky
- Baptist Health - Lexington — Lexington, Kentucky
- Baptist Health - Louisville — Louisville, Kentucky
- Minnesota Oncology Hematology — Maple Grove, Minnesota
- Missouri Cancer Associates — Columbia, Missouri
- White Plains Hospital Physician Associates — White Plains, New York
- Carolina Cancer Research Center — Wilson, North Carolina
- Oncology Hematology Care — Cincinnati, Ohio
- The Ohio State University - Arthur James Cancer Hospital & Solove Research Institute — Columbus, Ohio
- Mid Ohio Hem/ Onc dba The Mark H Zangmeister Center — Columbus, Ohio
- Oncology Associates of Oregon (Willamette Valley Cancer Institute and Research Center) — Eugene, Oregon
- Tennessee Cancer Specialists — Knoxville, Tennessee
- SCRI Oncology Partners — Nashville, Tennessee
📞 Contact the Study Coordinator
Phone: (844) 710-6157
Email: SCRI.InnovationsMedical@scri.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Limited Stage Small Cell Lung Cancer
Explore by condition: All Limited Stage Small Cell Lung Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.